Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.
Study Type
OBSERVATIONAL
Enrollment
1,000
Participants will receive standard clinical care as determined by their treating physicians. Treatment strategies, including antiarrhythmic drug therapy, catheter ablation, implantable cardioverter-defibrillator (ICD) implantation, cardiac resynchronization therapy with defibrillator (CRT-D), surgical interventions, and other clinically indicated therapies, will be recorded. No treatment is assigned or influenced by the study protocol.
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
RECRUITINGComposite of ventricular tachycardia recurrence or appropriate ICD therapy, unplanned cardiovascular hospitalization, or all-cause death
Time to the first occurrence of ventricular tachycardia recurrence or appropriate implantable cardioverter-defibrillator (ICD) therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death.
Time frame: 12 months
Ventricular tachycardia recurrence or appropriate ICD therapy
Time to the first documented ventricular tachycardia recurrence or first appropriate implantable cardioverter-defibrillator (ICD) therapy, when applicable.
Time frame: 12 months
Unplanned cardiovascular hospitalization
Time to the first unplanned hospitalization for cardiovascular causes.
Time frame: 12 months
Causes and number of unplanned cardiovascular hospitalizations
Causes of unplanned cardiovascular hospitalizations and the total number of hospitalization episodes during follow-up.
Time frame: 12 months
Causes and number of cardiovascular emergency department visits
Causes and total number of emergency department visits for cardiovascular conditions during follow-up.
Time frame: 12 months
All-cause mortality
Death from any cause during follow-up.
Time frame: 12 months
Cardiovascular mortality
Death attributable to cardiovascular causes during follow-up.
Time frame: 12 months
Change in health-related quality of life (SF-36)
Change in the Short Form-36 (SF-36) score from baseline.
Time frame: Baseline to 12 months
Change in patient-reported outcome measures
Change from baseline in patient-reported outcomes, including the Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Pittsburgh Sleep Quality Index (PSQI), and other validated scales, as applicable.
Time frame: Baseline to 12 months
Treatment-related major safety events
Occurrence of treatment-related major safety events, including catheter ablation-related complications, ICD-related complications, serious adverse drug reactions, and other serious adverse events.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.